|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 248.65 DKK | +1.30% |
|
+4.21% | -23.55% |
| 03-05 | Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial | DJ |
| 03-05 | Roche, Zealand's obesity drug shows up to 10.7% weight loss in mid-stage trial | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 170B | |||||
| 897B | |||||
| 591B | |||||
| 418B | |||||
| 368B | |||||
| 313B |
- Stock Market
- Equities
- NOVO B Stock
- Charts Novo Nordisk A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition